The expert panel of the Indian drug regulator is likely to meet again soon to review applications filed by Serum Institute of India (SII) and Bharat Biotech for full market approval to their respective Covid-19 vaccines.
The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) had met on Friday (14 January) to decide on full market approval to Bharat Biotech's Covaxin and SII's Covishield Covid vaccine.
However, the SEC could not finish the review on Friday due to the "huge amount of data" related to the two vaccines, reports Economic Times.
"The data is huge which has to be reviewed and it needs a considerable amount of time. The SEC will meet in the next 1-2 days to finish the review," people in the know of the matter were quoted in the ET report as saying.
Both, Covaxin and Covishield are the main Covid-19 vaccines being used in the government's vaccine drive that began in January last year. Both the vaccines have been authorised for emergency use in the country.
A market authorisation label for a vaccine means it can be authorised for use without any reservations or conditions.
Bharat Biotech had on Thursday (13 January) sought regular market approval from the drug regulator for its indigenous Covid-19 vaccine Covaxin.
Earlier last month, SII had also filed an application for full market approval to Covishield.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.